MERCK signed collaboration agreement with Sysmex Inostics GmbH for the development and commercialization of a blood-based RAS biomarker test for patients with metastatic colorectal cancer.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
